Dr Reddy's Laboratories Share Price
(DRREDDY)
₹1197.45▲0.03%
as on 01:50PM, 17 Feb 2025
🔔 Market Challenge Alert
Dr. Reddys Laboratories could face challenges in FY27 due to pricing pressures and margin erosion impacting US market earnings.
Dr Reddy's Laboratories Performance
Day's Low
Day's High
₹1,183.15Day's Price Range₹1,20252 Week's Low
52 Week's High
₹1,12052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | -8.58 % |
| 3 Month Return | + 0.29 % |
| 1 Year Return | -6.73 % |
| Market Stats | |
| Previous Close | ₹1,197.05 |
| Open | ₹1,196.40 |
| Volume | 12.12L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹99,884.72Cr |
Dr Reddy's Laboratories Key Statistics
P/E Ratio
18.56
PEG Ratio
11.39
Market Cap
₹99,884.72 Cr
P/B Ratio
4.22
EPS
66.882
Dividend Yield
0.65
Sector
Pharmaceuticals
ROE
19.42
Dr Reddy's Laboratories Mutual Fund Holdings
Dr Reddy's Laboratories Analyst Rating
based on 39 analysts
35.90%
Buy
28.21%
Hold
35.90%
Sell
Based on 39 analysts offering long term price targets for Dr Reddy's Laboratories. An average target of ₹1347.43
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share analysis
Dr Reddy's Laboratories price forecast by 39 analysts
Upside of12.56%
High
₹1723
Target
₹1347.43
Low
₹961
Dr Reddy's Laboratories target price ₹1347.43, a slight upside of 12.56% compared to current price of ₹1197.45. According to 39 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:24.73%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
08:29 AM
-Dr. Reddys Laboratories could face challenges in a bear-case scenario alongside other major pharmaceutical firms.
Key events for Dr Reddys Laboratories Ltd
Dr. Reddys Faces Potential Challenges Ahead - 17 Feb, 2025
Dr. Reddys Laboratories, along with other leading pharmaceutical companies, may encounter significant challenges due to pricing pressures and margin erosion affecting US market earnings.Dr. Reddy's Secures Major Biosimilar Deal - 06 Feb, 2025
Dr. Reddy's Laboratories has entered a significant licensing agreement with Shanghai Henlius Biotech for the development and commercialization of HLX15, a biosimilar to Darzalex, with exclusive rights in the U.S. and Europe. The deal is valued at up to $131.6 million, enhancing Dr. Reddy's oncology portfolio in regulated markets.Dr. Reddy's Faces Penalty Over GST Refund Issue - 02 Feb, 2025
Dr. Reddy's Laboratories has been ordered to pay a ₹184 crore penalty for receiving an excess GST refund. The company plans to appeal the decision, stating no material impact on its operations.Union Budget and Market Impact on Dr Reddy's - 01 Feb, 2025
The Union Budget 2025-26 is seen as beneficial for the pharmaceutical sector, with potential boosts to R&D and healthcare. However, Dr Reddy's faced losses amid market fluctuations.Positive Developments for Dr. Reddy's Laboratories - 31 Jan, 2025
Dr. Reddy's Laboratories is anticipated to benefit from a Production-Linked Incentive (PLI) scheme for anti-diabetic and weight-loss medications, boosting investor sentiment.Dr Reddy's Labs Reports Q4 2024 Financials - 28 Jan, 2025
Dr Reddy's Laboratories reported consolidated net sales of Rs 8,381.20 crore for December 2024, up 15.81% YoY. Net profit increased by 2.38% to Rs 1,413.70 crore, while EBITDA rose 8.21%. However, EPS decreased significantly to Rs 16.97. The stock closed at Rs 1,197.65, reflecting a -12.45% return over the last six months.Dr Reddy's Target Price Adjusted Amid Challenges - 27 Jan, 2025
KR Choksey has reduced the target price for Dr Reddy's Laboratories to Rs 1,245, citing increased competition and pricing pressures, while maintaining a HOLD rating.Dr Reddy's Stock Drops After Q3 Earnings Report - 25 Jan, 2025
Dr Reddy's Laboratories reported a 2% profit increase in Q3 2025, but shares declined nearly 7% as investors reacted negatively to the results. Revenue rose to ₹8,359 crore, but the stock's performance reflected investor disappointment.Dr Reddy's Reports Strong Q3 Earnings Growth - 23 Jan, 2025
Dr Reddy's Laboratories announced a 2.5% increase in net profit for Q3 FY25, reaching ₹1,413.3 crore, with revenue up 16% driven by the NRT portfolio. The company also highlighted strong performance in emerging markets and India, despite challenges from patent expirations. Overall, the results reflect solid growth and strategic investments in innovation.Dr. Reddy's Faces Bearish Momentum Ahead of Q3 Earnings - 22 Jan, 2025
Dr. Reddy's Laboratories is expected to report mixed Q3 results, with stable revenue growth but margin pressures due to lower Revlimid contributions and subdued US sales. Analysts anticipate a challenging quarter, leading to bearish sentiment in the stock market.Dr Reddy's Excels in US Export Market - 21 Jan, 2025
Dr Reddy's Laboratories is performing well in exports, particularly benefiting from the key US market, alongside other pharmaceutical companies.Dr Reddy's Labs Q3 Preview Shows Positive Growth - 20 Jan, 2025
Dr Reddy's Laboratories is projected to see a 14.7% revenue increase and a 12% rise in net profit for Q3 FY25, driven by domestic growth and gRevlimid sales. Analysts emphasize the importance of management commentary on US business trends.Dr Reddy's Laboratories Prepares for Earnings Announcement - 19 Jan, 2025
Dr Reddy's Laboratories is set to announce its quarterly results soon, with a notable revenue growth of 15.6% in Q2FY24-25. The company is also launching a generic version of Wegovy.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 9.97% to 10.22% in Dec 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.86% to 11.14% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Dec 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 7 days, DRREDDY stock has moved down by -2.0%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 27.53% to 26.85% in Dec 2024 quarter
News
Hindustan Unilever and Reliance Consumer Launch New Hydration Products
Reliance Consumers Spinner is a sports drink for the masses priced at Rs 10 a bottle. With Spinner, we've created an affordable and effective hydration solution that can be enjoyed by everyone. At a disruptive price of Rs 10 a bottle, Mody argues that Reliance is looking to do in the estimated Rs 240-crore sports drinks what it has done across categories — from telecom to media to FMCG — reduce entry barriers and give more people the chance to sample products.17 Feb, 2025 09:19 AMWill Sensex, Nifty break 8-day losing streak? RIL, Wipro, BHEL in focus
The Mukesh Ambani-led company has acquired project SPV Lakadia B Power Transmission Ltd, marking its entry in the power transmission development space.17 Feb, 2025 08:42 AMBrokerage Upgrades and Target Price Revisions for Key Stocks
Jefferies maintains Buy, sets a target price of ₹1,660, highlighting its diversified business expansion.17 Feb, 2025 08:01 AMDr Reddy's Laboratories Financials
Index Inclusions
Dr Reddy's Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 26.85% | ||
| Mutual Funds | 11.14% | 2.57 | |
| Retail Investors | 10.22% | 2.49 | |
| Others | 25.15% | 0.64 |
Dr Reddy's Laboratories Key Indicators
Dr Reddy's Laboratories Valuation
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (18.56x)
February 14, 2025
Industry (53.06x)
February 14, 2025
Highest (53.88x)
December 18, 2020
Dr Reddy's Laboratories Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 2.38% since last year same period to ₹1,413.70Cr in the Q3 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.58% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.68%.
Read More about Dividends
Dr Reddy's Laboratories Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
Dr Reddy's Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹99,884.72 Cr | 16.32% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,55,133.20 Cr | 34.24% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,01,997.80 Cr | 36.25% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹41,942.96 Cr | 3.05% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹24,043.87 Cr | -3.96% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹1197.45 per share as on 17 Feb, 2025 01:50 PM
Market Capitalisation: ₹99,884.72Cr as of today
Revenue: ₹8,358.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,404.20Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddy's Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Dr Reddys Laboratories Ltd
What is Dr Reddys Laboratories Ltd price today?
Dr Reddys Laboratories Ltd share price today stands at ₹1197.45, Open: ₹1196.4, Previous Close: ₹1197.05, High: ₹1202, Low: ₹1183.15, 52 Week High: ₹1421.49, 52 Week Low: ₹1120.
How to Buy Dr Reddys Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Dr Reddys Laboratories Ltd shares
Is Dr Reddys Laboratories Ltd listed on NSE?
Dr Reddys Laboratories Ltd is listed on NSE
Is Dr Reddys Laboratories Ltd listed on BSE?
Dr Reddys Laboratories Ltd is listed on BSE
What are today's High and Low prices of Dr Reddys Laboratories Ltd?
- Today's highest price of Dr Reddys Laboratories Ltd is ₹1202.
- Today's lowest price of Dr Reddys Laboratories Ltd is ₹1183.15.
What are today's traded volumes of Dr Reddys Laboratories Ltd?
Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 12.12L.
What is today's market capitalisation of Dr Reddys Laboratories Ltd?
Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹99884.72Cr.
What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?
How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1197.45. It is down -15.76% from its 52 Week High price of ₹1421.49
How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1197.45. It is up 6.92% from its 52 Week Low price of ₹1120
What are the historical returns of Dr Reddys Laboratories Ltd?
What is the PE ratio of Dr Reddys Laboratories Ltd today?
PE Ratio of Dr Reddys Laboratories Ltd is 18.56
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share